Roche's Third-Quarter Sales Performance

By Ludwig Burger

FRANKFURT (Reuters) – Roche's third-quarter sales increased by a currency-adjusted 9%, surpassing market expectations due to higher prescriptions for the monthly haemophilia injection, Hemlibra, and the newly launched eye medication, Vabysmo.

Financial Highlights

Group sales reached 15.14 billion Swiss francs ($17.46 billion), exceeding the analysts' consensus estimate of 14.9 billion francs, according to LSEG data.

Future Outlook

On Wednesday, the Swiss drugmaker reaffirmed its expectation for growth in 2024 adjusted earnings per share in the "high single-digit range," excluding the effects of currency fluctuations and the resolution of tax disputes in 2023.

($1 = 0.8671 Swiss francs)